A Senate Finance Committee found that a top FDA official overruled the unanimous opinion of his scientific staff when he decided last year to approve a pacemaker-like device to treat persistent depression, according to an article in the New York Times. The device has been used since 1997 to treat epilepsy, and when patients began reporting improvements in mood, the manufacturer sought approval for depression.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.